Optimizing the Ocular Surface Before and After Cataract Surgery
The role of perfluorohexyloctane in dry eye management
By
Justin Schweitzer
April 8, 2026
Clinical Scorecard: Optimizing the Ocular Surface Before and After Cataract Surgery
At a Glance
Category Detail
Condition Dry Eye Disease (DED) Key Mechanisms Use of perfluorohexyloctane ophthalmic solution (PFHO) to stabilize ocular surface and improve dry eye symptoms. Target Population Patients undergoing cataract surgery with dry eye disease. Care Setting Ophthalmology clinics and surgical centers.
Key Highlights
PFHO treatment did not negatively affect refractive outcomes. Significant improvement in ocular surface health and dry eye symptoms. Postoperative best-corrected visual acuity (BCVA) improved with continued PFHO therapy. High percentage of patients achieved optimal IOL calculation accuracy post-treatment. PFHO therapy resulted in normalization of OSDI scores by study end. Guideline-Based Recommendations
Diagnosis
Assess dry eye symptoms and ocular surface health preoperatively. Management
Utilize PFHO for managing dry eye before and after cataract surgery. Monitoring & Follow-up
Monitor ocular surface health and visual outcomes post-surgery. Risks
Consider potential impacts of untreated dry eye on surgical outcomes. Patient & Prescribing Data
Patients with severe dry eye symptoms undergoing cataract surgery.
PFHO can be administered four times daily for 30 days pre- and postoperatively without compromising surgical measurements.
Clinical Best Practices
Optimize ocular surface health before cataract surgery. Continue dry eye treatment postoperatively to enhance visual outcomes. Evaluate and document changes in ocular surface metrics and patient-reported outcomes. Related Resources & Content
